If you’ve ever walked through a pharmaceutical manufacturing facility—whether it’s a lab working on sterile injectables or a production line packaging over-the-counter tablets—you’ve probably wondered how teams keep materials moving without risking contamination, consistency, or delays. As a conveying line supplier with 12 years of serving pharma, biotech, and nutraceutical plants, I get this question all the time: Can a conveying line actually work in a pharmaceutical factory? The short answer is yes—but only if it’s designed for the unique, non-negotiable rules of drug manufacturing, not just the standard lines used in food or general assembly. Let me break down how that works, the standards I adhere to when building these systems, and why skipping the “pharma-specific” step can turn a cost-saving equipment choice into a compliance nightmare. Conveying Line
First, let’s get one critical fact straight: Pharmaceutical conveying lines aren’t the same as the ones you see moving cereal boxes in a food processing plant or car parts in an auto factory. Those lines can get dusty, leak, or be wiped down with a quick spray, but pharma lines are built to meet regulatory requirements that don’t budge. In the U.S., that means alignment with the FDA’s Current Good Manufacturing Practices (CGMPs), specifically 21 CFR Part 210 and 211, which outline everything from material safety to process validation. Globally, we follow WHO Good Manufacturing Practices (GMPs) and EU GMP Annex 1, which governs sterile drug production. These aren’t just guidelines—they’re legal rules that can lead to shutdowns, fines, or product recalls if violated.
When I first started in this industry 12 years ago, many pharma plant operators saw conveying lines as an afterthought. They’d grab a standard belt conveyor from a general supplier, install it, and within a year run into problems. I remember one early client—a mid-sized generic drug manufacturer—came to me in 2015 with a costly issue: their tablet coating line was running at 72% efficiency, because the standard plastic belt they’d imported was shedding micro-plastics into the product. The FDA’s 2014 guidance on material safety for pharma manufacturing called out such particulate shedding as a “serious risk of adulteration,” and they’d just received a warning letter. That experience taught me that pharma conveying lines have to be engineered from the ground up for cleanliness, not just movement.
So what makes a conveying line pharma-ready? Let’s start with materials. Every part that touches the drug product, excipients, or active pharmaceutical ingredients (APIs) has to be non-reactive, non-toxic, and free of leachables and extractables—substances that can seep into the drug over time and contaminate it. No cheap rubber belts, no galvanized steel, no plastics with BPA or phthalates. For most APIs and solid oral dose products, we use 316L stainless steel for all product-contact surfaces. It’s easy to sanitize, resistant to corrosion from common cleaning agents like hydrogen peroxide and ethanol, and doesn’t shed particles. For applications that need a gentle touch—like moving fragile oncology tablets that crack easily—we use medical-grade, FDA-approved silicone belting, not the food-grade stuff that often has additives not cleared for pharma.
Next, design for cleanability, or CIP (Clean-in-Place) capability, which is non-negotiable for pharma. Unlike general manufacturing lines that require parts to be taken apart and washed manually, a good pharma conveying line can be sanitized without disassembly. That means no hidden crevices, dead legs, or sharp corners where product can get trapped and grow bacteria. We design conveyors with sloped surfaces that allow all liquid and residue to drain completely, and we use tri-clamp connections—those quick, bolted fittings that are standard in biotech plumbing—so we can connect the entire line to a CIP skid that pumps hot, sanitizing solution through it. For example, when working with a monoclonal antibody (mAb) processing plant last year, we built a vertical screw conveyor that transported cell culture media between bioreactors and filtration systems. We eliminated every horizontal seam, and the screw flights were polished to a 20 Ra surface finish (a measure of smoothness, where lower numbers are smoother) so no media residue stuck. The plant’s validation team was able to complete their CIP qualification test in half the time of their old line, which used flanged connections that trapped particles.
Validation is another key piece that general conveying suppliers almost never address. For pharma, you can’t just install a line and start running product; you have to prove that it consistently works as intended, and that it doesn’t introduce risk. That means providing detailed documentation for every component, running performance tests, and ensuring the line meets the client’s specific needs—whether that’s moving potent APIs that require containment, sterile materials that need isolation, or fragile dosage forms that need minimal vibration. When a client is working with a potent cytotoxic API, for example, we design the line to be a closed system—so no dust escapes into the air, and no external contaminants get in. We include pressure monitoring and HEPA filters to maintain the required air quality, and we run leak tests to confirm that the line meets OSHA and FDA requirements for potent material handling. The documentation for that test isn’t just a receipt; it’s part of the client’s regulatory submission to the FDA, so we make sure every step is recorded in a format that works for their auditors.
Contamination risk is where most non-specialized lines fall short. Pharma products are incredibly sensitive—even a tiny amount of cross-contamination from another drug, or residual cleaning agent left on a conveyor, can ruin an entire batch and trigger a recall. I had a client in 2018, a contract development and manufacturing organization (CDMO), that handled 12 different generic drugs for a big pharma client. They installed a standard conveyor between their granulation and tablet pressing lines, and within three months, they got a surprise: the drug recall for one batch of metformin showed trace amounts of another drug, lisinopril, at a level just below the FDA’s limit for cross-contamination. The standard conveyor had a worn belt that had absorbed small amounts of lisinopril over time, and even with cleaning, it couldn’t remove it. We redesigned their conveying system to have quick-release, dedicated segments for each drug, made of the same 316L stainless steel, and added a validation step for changeover between products. That CDMO has run 80+ product lines since then with zero cross-contamination events, and they now recommend our systems to every new client handling multiple drugs.
Another common misconception is that conveying lines will “slow down” pharma production. The opposite is true when they’re designed right. When a line is built for GMP, easy cleaning, and low maintenance, downtime drops dramatically. I worked with a small biotech firm in 2021 that was scaling up a mRNA vaccine candidate. They had been moving vials of purified mRNA by hand between their purification, filtration, and filling lines— a process that took 6 hours a day and had a 12% error rate, with some vials getting dropped. We installed a custom monorail conveying line that was compatible with their Class 10,000 cleanroom (a space with strict limits on airborne particles). The line was operated with programmable logic controllers (PLCs) that could sync with their filling and packaging equipment, so vials moved exactly when needed, no manual handling required. Their downtime for changeover and cleaning dropped by 40%, and error rates went to almost zero. They’re now scaling to full commercial production, and the conveying line is a core part of their process, not a bottleneck.
Now, I’m not here to say that every conveying line works in every pharma factory. There are cases where a traditional conveyor might not be suitable, but those are exceptions, not the rule. For example, some very small-scale clinical trial facilities, where batches are only a few thousand units, might use manual transport to avoid the cost of a custom line. But as those facilities scale to commercial production, they almost always switch to automated conveying systems. The key is partnering with a supplier that understands both the technical requirements of conveying and the regulatory landscape of pharma—not just a supplier that can quote a low price for a standard belt.
Over the years, I’ve heard every argument against using conveying lines in pharma: “It’s too risky,” “It will fail inspection,” “Our process is too unique.” But the data doesn’t lie. The FDA’s most recent report on manufacturing efficiency shows that facilities with validated, pharma-specific conveying lines reduce batch failure rates by 28% and cut production costs by 15% on average, because of lower labor and less wasted product. Those numbers are hard to ignore when you’re trying to get a drug to market faster and stay compliant.
If you’re a pharma plant operator, CDMO, or biotech startup looking to upgrade your material transport, the first step isn’t to shop for the cheapest equipment. It’s to talk to a supplier that has actual experience in pharma, not just general manufacturing. Ask for references from other clients in your niche—whether you’re making sterile injectables, oral tablets, APIs, or biologic products. Ask about their process validation support, the materials they use for product contact, and their CIP capabilities. And be honest about your biggest pain points: cross-contamination, downtime, compliance risk. A good conveying line supplier won’t just sell you a machine; they’ll work with your team to design a system that fits your process, meets all regulations, and actually makes your operations better.
At the end of the day, pharmaceutical manufacturing is all about consistency, safety, and trust. Patients around the world rely on the drugs we make to stay healthy, and every step of the process has to uphold that standard. A well-designed conveying line isn’t just a piece of equipment—it’s a critical part of ensuring that every batch of drug is pure, on time, and meets the highest regulatory standards. It’s not a risk to avoid; it’s a tool that can help your facility thrive, as long as you choose the right partner to build it.
If you’re ready to explore a conveying line that’s tailored to your pharmaceutical operations, don’t hesitate to reach out for a confidential consultation. We’ll walk through your process, address your specific concerns, and help you find a solution that balances compliance, efficiency, and reliability.
Autonomous Mobile Robot References
- U.S. Food and Drug Administration. (2004). Current Good Manufacturing Practice for Finished Pharmaceuticals (21 CFR Parts 210 and 211).
- World Health Organization. (2019). WHO Good Manufacturing Practices for Pharmaceutical Products.
- European Commission. (2023). EU GMP Annex 1: Manufacture of Sterile Medicinal Products.
- U.S. Food and Drug Administration. (2014). Guidance for Industry: Container and Closure System Integrity.
- International Society for Pharmaceutical Engineering (ISPE). (2021). ISPE Good Practice Guide: Process Conveying and Transport in Pharmaceutical Manufacturing.
Shenzhen Ginnee Intelligent Warehousing Robotics Co., Ltd.
As one of the most professional conveying line suppliers in China, we’re featured by quality products and low price. Please rest assured to wholesale durable conveying line in stock here and get quotation from our factory. We also accept customized orders.
Address: Room101, No.162 JunXin Road, Niuhu Community, Guanlan Strect, Longhua District, Shenzhen, Guangdong Province, China.
E-mail: huangyongmei@szginnee.com
WebSite: https://www.ginneerobotics.com/
